Statera Biopharma, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Revenues:
Grants and contracts
Cost of Revenue:
Cost of goods sold
Gross Profit
Operating expenses:
Research and development
Sales and marketing expense
General and administrative
Impairment loss
Total operating expenses
Loss from operations
Other income (expense):
Interest and other income (expense)
Foreign exchange gain (loss)
Gain on investment provision
Change in value of warrant liability
Gain on extinguishment of debt
Total other income (expense)
Income from discontinued operations, net of income taxes
Net loss
Net loss attributable to noncontrolling interests
Net loss attributable to Cleveland BioLabs, Inc.
Net loss attributable to Statera Biopharma, Inc.
Net loss available to common stockholders per share of common stock, basic and diluted (in dollars per share)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)

Comments